Display options
Cite
Tłustochowicz M, Śliwczyński AM, Brzozowska M, et al. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. Arch Med Sci. 2016;14(3):569-571doi: 10.5114/aoms.2016.58924.
Tłustochowicz, M., Śliwczyński, A. M., Brzozowska, M., Teter, Z., & Marczak, M. (2018). Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. Archives of medical science : AMS, 14(3), 569-571. https://doi.org/10.5114/aoms.2016.58924
Tłustochowicz, Małgorzata, et al. "Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014." Archives of medical science : AMS vol. 14,3 (2018): 569-571. doi: https://doi.org/10.5114/aoms.2016.58924
Tłustochowicz M, Śliwczyński AM, Brzozowska M, Teter Z, Marczak M. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. Arch Med Sci. 2018 Apr;14(3):569-571. doi: 10.5114/aoms.2016.58924. Epub 2016 Mar 31. PMID: 29765444; PMCID: PMC5949902.
Copy Download .nbib Format: NLM
Share it on

Arch Med Sci. 2018 Apr;14(3):569-571. doi: 10.5114/aoms.2016.58924. Epub 2016 Mar 31.

Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014.

Archives of medical science : AMS

Małgorzata Tłustochowicz, Andrzej M Śliwczyński, Melania Brzozowska, Zbigniew Teter, Michał Marczak

Affiliations

  1. Rheumatology Department, Military Medical Institute, Warsaw, Poland.
  2. Department of Quality, Procedures and Medical Standards, Medical University of Lodz, Lodz, Poland.
  3. National Health Fund, Warsaw, Poland.

PMID: 29765444 PMCID: PMC5949902 DOI: 10.5114/aoms.2016.58924

Abstract

Approximately 1% of the population suffers from rheumatoid arthritis (RA) worldwide (0.45% in Poland). The therapy consists of the use of disease-modifying antirheumatic drugs (DMARDs). Biologics are used in the form of the drug programme. Analysis of the NHF database demonstrated the sequence of conversion between drugs and time spent in a single treatment. In 2009, the patients would start the following treatments: adalimumab 5.8%; etanercept 14.4%; infliximab 23.1%; leflunomide 53.6%; rituximab 3%. After the first year 16% of patients changed therapy or abstained, and in the second year this situation affected 65% of patients. The following percentages maintained the same treatment in the last 6 years: infliximab 4%; adalimumab 15%; etanercept 21%; leflunomide on prescription was continued by 70%. Patients remain too long on the same therapy when it is inefficient. Achieving remission or low disease activity (DAS28 < 2.6) should take place within 6 months of starting therapy.

Keywords: biological drug; rheumatoid arthritis; sequentiality of treatment

References

  1. Ann Rheum Dis. 2010 Sep;69(9):1580-8 - PubMed
  2. Arthritis Rheum. 2006 May;54(5):1390-400 - PubMed
  3. Arthritis Rheum. 2004 Nov;50(11):3432-43 - PubMed
  4. Ann Rheum Dis. 2014 Mar;73(3):492-509 - PubMed
  5. Lancet. 2004 Feb 28;363(9410):675-81 - PubMed
  6. Arch Med Sci. 2014 Dec 22;10(6):1175-85 - PubMed

Publication Types